Welcome to InSimili website!
Who we are
The cost of developing new pharmaceuticals from synthesis to marketing approval is estimated in 2.8 billion dollar per drug. New drug development is a lengthy and risky process, with many compounds failing for every one that succeeds.
Who we are
InSimili is a spinoff of the University of Bologna established in February 2021. Here at our startup, we are passionate about innovation and progress in the field of drug testing. We are a team of experts from diverse disciplines, including chemistry, biology, nanoscience, and computer science. Our mission is to develop innovative solutions that can improve the preclinical phase and contribute to addressing unmet health needs.
By focusing on these unaddressed health needs, we aim to contribute to a healthier future for individuals, communities, and societies as a whole. Our interdisciplinary approach, cutting-edge technologies, and collaborative partnerships enable us to make a meaningful difference in the field of life sciences. Together, we can pave the way for improved health outcomes and a better quality of life for all.
At InSimili, we deeply value:
- Research and Development: As University spin-off we invest time and resources in scientific research to develop new products and technologies that can make a difference in the field of life sciences.
- Innovation: as innovative startup we develop cutting-edge solutions bringing innovation to the market.
- Collaborations: We have strategic collaboration with several research organization, to advance our shared mission of improving drug prediction in preclinical phases. We believe in the importance of synergies and complementary expertise to tackle the complex challenges of our world.